EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections

Veeral S Sheth, Nancy M Holekamp, Arshad M Khanani, Aleksandra Rachitskaya, Steven Blotner, Shamika Gune, Dominic Heinrich, Katie F Maass, Usha Chakravarthy

Ophthalmology Retina · 2025-04 · 9 (4) · 330-342

DOI: 10.1016/j.oret.2024.10.015 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2025-04. Verfasst von Veeral S Sheth und 8 weiteren Autor:innen. Beteiligte Einrichtung: University Retina, Oak Forest, Illinois. Electronic address: vsheth@gmail.com. Hauptthemen laut MEDLINE: Ranibizumab, Visual Acuity, Tomography, Optical Coherence, Wet Macular Degeneration. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche, F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To determine proportion of eyes with neovascular age-related macular degeneration (nAMD) with retinal fluid and central subfield thickness (CST) fluctuations and evaluate their impact on best-corrected visual acuity (BCVA) in eyes treated with the Port Delivery System with ranibizumab (PDS) versus monthly intravitreal ranibizumab injections. DESIGN: Post hoc analyses of phase 3 Archway trial (NCT03677934). PARTICIPANTS: Adults with nAMD responsive to anti-VEGF therapy. INTERVENTION: Four hundred eighteen patients randomized 3:2 to the PDS (100 mg/mL) with refill-exchanges every 24 weeks (Q24W) or monthly intravitreal ranibizumab (0.5 mg) for 96 weeks. OUTCOMES: Proportion of eyes in each treatment arm with subretinal and/or intraretinal fluid (SRF/IRF) overall and in central 1 mm; BCVA changes from baseline by treatment arm and fluid presence/location; proportion of eyes with CST fluctuations from baseline to week 48, week 48 to 96, and baseline to week 96; effects of CST fluctuations on BCVA. RESULTS: Four hundred fifteen eyes were assessed. In the PDS versus monthly ranibizumab arm, proportion of eyes with SRF/IRF, central SRF, and central IRF were 47.6% versus 50.9%, 29.0% versus 19.2%, and 11.7% versus 12.6% at baseline, and 57.8% versus 56.1%, 21.6% versus 14.8%, and 7.0% versus 8.4% at week 96, respectively. BCVA changes from baseline to week 96 were -1.1 letters with the PDS versus -1.4 with monthly ranibizumab in eyes with SRF/IRF, and -1.9 versus -1.8 in eyes with central SRF. In eyes with central IRF, BCVA changes from baseline to week 96 were -2.1 with the PDS versus -6.9 with monthly ranibizumab, respectively (mean BCVA at 96 weeks 68.9 [20/40] vs. 64.6 [20/50]). CST fluctuations occurred in 32.1% and 29.7% of PDS versus monthly ranibizumab eyes; corresponding BCVA changes from baseline to week 96 were -2.5 versus -2.6 (mean BCVA at 96 weeks 72.7 [20/35] vs. 71.5 [20/38]). CONCLUSIONS: Port Delivery System with ranibizumab Q24W maintained BCVA to 96 weeks regardless of SRF/IRF, central SRF, central IRF, or CST fluctuations, comparable with monthly ranibizumab, thus supporting the use of the PDS in stabilizing retinal anatomy without the need for monthly treatment in patients with nAMD. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RanibizumabVisual AcuityTomography, Optical CoherenceWet Macular DegenerationSubretinal FluidRetinaDrug Delivery SystemsHumansIntravitreal InjectionsMaleAngiogenesis InhibitorsFemaleAgedFollow-Up StudiesVascular Endothelial Growth Factor AMiddle AgedFluorescein AngiographyAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Anti-VEGFNeovascular age-related macular degenerationPort Delivery System with ranibizumabRetinal fluidRetinal thicknessVisual acuity

Substanzen

RanibizumabAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • University Retina, Oak Forest, Illinois. Electronic address: vsheth@gmail.com.
  • Pepose Vision Institute, Chesterfield, Missouri; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Sierra Eye Associates, Reno, Nevada; University of Nevada, Reno School of Medicine, Reno, Nevada.
  • Cleveland Clinic, Cleveland, Ohio.
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Genentech, Inc, South San Francisco, California.

Förderung

  • Roche
  • F. Hoffmann-La Roche

Zitieren

APA

Sheth, V. S., Holekamp, N. M., Khanani, A. M., Rachitskaya, A., Blotner, S., Gune, S., Heinrich, D., Maass, K. F., & Chakravarthy, U. (2025). Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections. Ophthalmology Retina, 9(4), 330-342. https://doi.org/10.1016/j.oret.2024.10.015

Vancouver

Sheth VS, Holekamp NM, Khanani AM, Rachitskaya A, Blotner S, Gune S, et al. Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections. Ophthalmology Retina. 2025;9(4):330-342. doi:10.1016/j.oret.2024.10.015

BibTeX
@article{Sheth2025,
  author = {Sheth, Veeral S and Holekamp, Nancy M and Khanani, Arshad M and Rachitskaya, Aleksandra and Blotner, Steven and Gune, Shamika and Heinrich, Dominic and Maass, Katie F and Chakravarthy, Usha},
  title = {Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections},
  journal = {Ophthalmology Retina},
  year = {2025},
  volume = {9},
  number = {4},
  pages = {330--342},
  doi = {10.1016/j.oret.2024.10.015}
}
Kostenlos starten →